Yanli Wang
& Key Laboratory Of Cancer Prevention And Intervention, Ministry Of Education
Hangzhou, China
Hangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Correction: A Single-Center, Randomized, Open-Label, Two-Formulation, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of Two Eltrombopag Olamine Tablets (25 mg) in Healthy Chinese Subjects in the Fed State.
Journal: Clinical drug investigation
Published: April 30, 2026
Interpretable multimodal deep learning improves postoperative risk stratification in intrahepatic cholangiocarcinoma in multicentre cohorts.
Journal: NPJ digital medicine
Published: October 14, 2025
Application of Problem-Oriented Nursing Model Combined with Early Enteral Nutrition Support in the Perioperative Period of Stage II/III Gastric Cancer Patients.
Journal: Nutrition and cancer
Published: July 21, 2025
A Single-Center, Randomized, Open-Label, Two-Formulation, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of Two Eltrombopag Olamine Tablets (25 mg) in Healthy Chinese Subjects in the Fed State.
Journal: Clinical drug investigation
Published: May 18, 2025
Primary cutaneous rhabdomyosarcoma with EWSR1/FUS::TFCP2 fusion: four new cases with distinctive morphology, immunophenotypic, and genetic profile.
Journal: Virchows Archiv : an international journal of pathology
Published: September 05, 2024
Food effect trial of the pharmacokinetics and safety of TQ05105 in healthy Chinese subjects.
Journal: Cancer chemotherapy and pharmacology
Published: August 21, 2024
A single-dose, randomized, crossover bioequivalence study of levamlodipine besilate tablets in healthy subjects.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: June 16, 2024
A novel molecular subtyping based on multi-omics analysis for prognosis predicting in colorectal melanoma: A 16-year prospective multicentric study.
Journal: Cancer letters
Published: November 30, 2023
Pharmacokinetics and safety of a new generic lurasidone: a phase I bioequivalence study in healthy Chinese subjects.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: October 30, 2023
Pharmacokinetics and bioequivalence of sunitinib and Sutent® in Chinese healthy subjects: an open-label, randomized, crossover study.
Journal: Frontiers in pharmacology
Published: September 15, 2023
A randomized, single-blind, single-dose, parallel-group study in healthy subjects to demonstrate the pharmacokinetic equivalence of trastuzumab and its biosimilar.
Journal: Expert opinion on drug metabolism & toxicology
Published: August 01, 2023
Last Updated: 09/26/2026